ArticlePloS one2025
Costs and return to scale analysis of extending the offer of pre-exposure prophylaxis (PrEP) to key populations aged 15-17 years old in two Brazilian cities.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In Brazil, HIV infection incidence is increasing, particularly among men who have sex with men (MSM) and transgender women (TGW). Pre-exposure prophylaxis (PrEP) is an effective prevention strategy, offered for free for those 15 years and over, in the Brazilian National Health System (SUS), but without a consistent demand creation strategy (DCS) to support the Sustainable Development Goals targets. The objectives of this study are to assess (1) the total incremental cost, and average total incremental costs of PrEP delivery, including DCS, targeting MSM and TGW adolescent aged 15-17 years old, and (2) the potential gains of scale for the expansion of PrEP at SUS, based on different scenarios to reach the UNAIDS goals for HIV targets. We estimated the total incremental and average total incremental cost, and the gains of scale for the expansion of PrEP delivery in SUS using Cobb-Douglas functions. The average total incremental cost per PrEP delivery was estimated at USD 321 in Salvador and USD 254 in São Paulo. Gains of scale were observed in both study settings and nationally for the Brazilian SUS. Our estimates show that investments in expanding PrEP delivery to 15-17 years old will likely reduce average total incremental costs to the Brazilian SUS. However, a cost-effectiveness analysis would be required to assess whether investments in an expansion of PrEP delivery would maximise the benefits of reducing the incidence of HIV/AIDS among the target population compared to the current Brazilian SUS practices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.